Last reviewed · How we verify
Heparin and Rivaroxaban
At a glance
| Generic name | Heparin and Rivaroxaban |
|---|---|
| Also known as | platelet collection |
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Epistaxis
- Vomiting
- Pyrexia
- Diarrhoea
- Cough
- Constipation
- Nasopharyngitis
- Nausea
- Abdominal pain
- Contusion
- Pain in extremity
Key clinical trials
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
- Anticoagulation in Patients With Venous Thromboembolism and Cancer
- The PEERLESS II Study (NA)
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis (NA)
- Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis (PHASE4)
- Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Heparin and Rivaroxaban CI brief — competitive landscape report
- Heparin and Rivaroxaban updates RSS · CI watch RSS
- First Affiliated Hospital Xi'an Jiaotong University portfolio CI